CEL-SCI CORPORATION APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
CEL-SCI CORPORATION (CVM) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $2.64 million for the 12-month period ending 2013-09-30, per its 10-K filed 2014-12-23.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2014-12-23
- CEL-SCI CORPORATION apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2013 was $2.64M, a 18.28% increase from fiscal 2012.
- CEL-SCI CORPORATION apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2012 was $2.23M.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|
| 2013-09-30 | $2.64M 10-K · filed 2014-12-23 |
| 2012-09-30 | $2.23M 10-K · filed 2014-12-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |